Skip to main content

Press releases | April 19, 2023

Fried Frank acted as counsel to Centerview Partners (“Centerview”) as financial advisor to BELLUS Health (“Bellus”) in its ~$2b acquisition by GSK. The acquisition provides GSK access to camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC. 

The Fried Frank team was led by partner Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.